High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
823.53M
+10.2%
0.931
+1.14%
818.93M
+9.9%
1.258
+11.33%
848.02M
+2.74%
1.303
-9.51%
Estimates Revision
The market is revising Downward the revenue expectations for BioMarin Pharmaceutical Inc. (BMRN) for FY2025, with the revenue forecasts being adjusted by -0.04% over the past three months. During the same period, the stock price has changed by -5.16%.
Revenue Estimates for FY2025
Revise Downward
-0.04%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-17.01%
In Past 3 Month
Stock Price
Go Down
-5.16%
In Past 3 Month
18 Analyst Rating
Wall Street analysts forecast BMRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMRN is 87.50 USD with a low forecast of 55.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Buy
4 Hold
0 Sell
Strong Buy
Current: 53.820
Low
55.00
Averages
87.50
High
120.00
Current: 53.820
Low
55.00
Averages
87.50
High
120.00
Leerink
Outperform -> Market Perform
downgrade
$60
2025-12-03
New
Reason
Leerink
Price Target
$60
2025-12-03
New
downgrade
Outperform -> Market Perform
Reason
Leerink downgraded BioMarin to Market Perform from Outperform with a $60 price target.
Leerink
Outperform -> Market Perform
downgrade
$82 -> $60
2025-12-03
New
Reason
Leerink
Price Target
$82 -> $60
2025-12-03
New
downgrade
Outperform -> Market Perform
Reason
Leerink downgraded BioMarin to Market Perform from Outperform with a price target of $60, down from $82. BioMarin's new leadership has taken decisive actions, including workforce reductions, ending the Roctavian program, restructuring the pipeline, and acquiring Inozyme, which support more credible long-term financial targets, but competitive pressure in achondroplasia and a sizable pipeline gap make future M&A central to the story, leaving uncertainty about whether these steps are enough to drive meaningful upside from here, the analyst tells investors in a research note.
Stifel
Buy -> Hold
downgrade
$73 -> $61
2025-11-06
Reason
Stifel
Price Target
$73 -> $61
2025-11-06
downgrade
Buy -> Hold
Reason
Stifel downgraded BioMarin to Hold from Buy with a price target of $61, down from $73.
Stifel
Paul Matteis
Buy
to
Hold
downgrade
$73 -> $61
2025-11-06
Reason
Stifel
Paul Matteis
Price Target
$73 -> $61
2025-11-06
downgrade
Buy
to
Hold
Reason
Stifel analyst Paul Matteis downgraded BioMarin to Hold from Buy with a price target of $61, down from $73. Even from what feels like an "impaired valuation," it is become harder for the firm to see BioMarin significantly outperforming over the next 12 months, barring a takeout, the analyst tells investors. This is due to competitive concerns for Voxzogo, which are "valid" given key opinion leader checks are "concerning," underlying Voxzogo growth trends that "aren't great" even before competition, and the view that the path to actually disproving the bear case is unclear.
Bernstein
Market Perform
downgrade
$95 -> $88
2025-11-03
Reason
Bernstein
Price Target
$95 -> $88
2025-11-03
downgrade
Market Perform
Reason
Bernstein lowered the firm's price target on BioMarin to $88 from $95 and keeps a Market Perform rating on the shares following quarterly results. The firm notes BioMarin delivered an in-line revenue print but missed on EPS due to consensus mis-modeling of AIPR&D for inozyme.
RBC Capital
Sector Perform
maintain
$70 -> $66
2025-10-28
Reason
RBC Capital
Price Target
$70 -> $66
2025-10-28
maintain
Sector Perform
Reason
RBC Capital lowered the firm's price target on BioMarin to $66 from $70 and keeps a Sector Perform rating on the shares. The company reported an in-line quarter given the Voxzogo miss was offset by the base business beat, the analyst tells investors in a research note. On Voxzogo, this is the very first down quarter since launch, and BioMarin notes some seasonality and a somewhat mixed uptake in older US kids, RBC added.
See All Ratings
Valuation Metrics
The current forward P/E ratio for BioMarin Pharmaceutical Inc (BMRN.O) is 11.22, compared to its 5-year average forward P/E of 40.57. For a more detailed relative valuation and DCF analysis to assess BioMarin Pharmaceutical Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Undervalued
5Y Average PE
40.57
Current PE
11.22
Overvalued PE
65.43
Undervalued PE
15.71
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
71.01
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
192.56
Undervalued EV/EBITDA
-50.53
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
6.24
Current PS
0.00
Overvalued PS
7.87
Undervalued PS
4.61
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
BMRN News & Events
Events Timeline
(ET)
2025-10-29
09:02:20
BioMarin: FDA Grants Priority Review for sBLA of Palynziq
2025-10-28 (ET)
2025-10-28
07:39:34
Stifel Reduces BioMarin Price Target from $91 to $73
2025-10-27 (ET)
2025-10-27
16:18:37
BioMarin announces Q3 adjusted earnings per share of 12 cents, surpassing consensus estimate of 7.6 cents.
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/4cb2b804b0a4f8562f956947643e530a89d08da5cb741bf81f66d0fab6484f15.png)
Preview
4.0
12-03BenzingaUber Expected to Surge by 43%? Check Out 10 Leading Analyst Predictions for Wednesday
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/104a7c36c1f7b464ffd6c8fc8c3580323adf2407558afc5a35381c4d18a0fdbc.png)
Preview
4.0
12-03BenzingaWayfair Analyst Changes Stance; Check Out Wednesday's Top 5 Downgrades
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/a0d67486bb41f068cff1faa48ccb3f40b9c570b3e0b20251a1c5acfd0fe7aa34.png)
Preview
1.0
11-11PRnewswireBioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England
Sign Up For More News
People Also Watch
FAQ
What is BioMarin Pharmaceutical Inc (BMRN) stock price today?
What is BioMarin Pharmaceutical Inc (BMRN)'s business?
What is the price predicton of BMRN Stock?
What is BioMarin Pharmaceutical Inc (BMRN)'s revenue for the last quarter?
What is BioMarin Pharmaceutical Inc (BMRN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for BioMarin Pharmaceutical Inc (BMRN)'s fundamentals?
How many employees does BioMarin Pharmaceutical Inc (BMRN). have?